ProShare Advisors
LUCD icon

ProShare Advisors’s Lucid Diagnostics LUCD Stock Holding History

ProShare Advisors’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.8K Buy
19,468
+6,400
+49% +$6.9K ﹤0.01% 1901
2026
Q1 		$15K Sell
13,068
-3,403
-21% -$4.33K ﹤0.01% 1845
2025
Q4 		$18K Buy
16,471
+4,320
+36% +$4.83K ﹤0.01% 2021
2025
Q3 		$12.3K Sell
12,151
-2,043
-14% -$2.23K ﹤0.01% 2002
2025
Q2 		$16.3K Buy
+14,194
New +$18.3K ﹤0.01% 2071

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

ProShare Advisors's LUCD Position: Q2 2026 in Review

ProShare Advisors increased its Lucid Diagnostics (LUCD) stake by 49% in Q2 2026, buying an estimated $6.9K and bringing the position to 19,468 shares worth $20.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1901.

ProShare Advisors first reported a position in LUCD in Q2 2025 and has held it in 5 quarters since. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • ProShare Advisors held 19,468 shares of Lucid Diagnostics worth $20.8K as of Q2 2026.
  • ProShare Advisors bought 6,400 Lucid Diagnostics shares in Q2 2026, an estimated $6.9K.
  • Lucid Diagnostics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1901 holding.
  • ProShare Advisors first reported a position in Lucid Diagnostics in Q2 2025 and has held it in 5 quarters since.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.